Tcr2 Therapeutics — Technical Presentation (July 2020)
27 slides from Tcr2 Therapeutics's technical presentation, Jul 27, 2020
Slide 1: Presentation of Clinical Data from First Cohort of TC-210 Patients
Exhibit 99.2 Presentation of Clinical Data from First Cohort of TC-210 Patients Trial ongoing with additional patients enrolled and treatedExhibit 99.2 Presentation of Clinical Data from First Cohort of TC-210 Patients Trial ongoing with additional patients enrolled and treated
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation has been prepared by TCR Therapeutics Inc. (“we,” “us,” or planned Phase 1 clinical trial of TC-110; the risk that the results from the Phase “our”) and contains forward-looking statements within the meaning of the Private 1/2 clinical trial of TC-210 w
Slide 3: Introduction
Introduction Garry Menzel, PhD Chief Executive Officer 3Introduction Garry Menzel, PhD Chief Executive Officer 3
Slide 4: Key Takeaways from Our First Cohort of TC-210 Patients
Key Takeaways from Our First Cohort of TC-210 Patients Clinical Trial Overview Key Clinical Findings § Data on first 5 patients: 4 patients with § Screening: 48% patients eligible mesothelioma, 1 with ovarian cancer § Manufacturing: 100% success rate § Single infusion of TC-210 TRuC-T Cells § Safety
Slide 5: Mesothelin Is an Excellent Solid Tumor Target
Mesothelin Is an Excellent Solid Tumor Target Mesothelin is highly expressed on tumors Expression Lower expression in normal tissue, No expression Patterns confined to mesothelium in pleura, in vital organs peritoneum and pericardium Target validation from competitor programs, including: Clinical Da
Slide 6: Mesothelin Solid Tumors Represent A Significant Market
Mesothelin Solid Tumors Represent A Significant Market Malignant Pleural Cholangiocarcinoma Ovarian Cancer NSCLC Mesothelioma 76% 50% 58% 31% 2,100 4,000 13,000 61,000 Market Opportunity: Market Opportunity: Market Opportunity: Market Opportunity: ~$700M ~$800M ~$1.6B ~$1.6B Fast Track Potential Per
Slide 7: TC-210 Clinical Trial Review
TC-210 Clinical Trial Review Alfonso Quintás-Cardama, MD Chief Medical Officer 7TC-210 Clinical Trial Review Alfonso Quintás-Cardama, MD Chief Medical Officer 7
Slide 8: Ongoing TC-210 Phase 1/2 Trial in MSLN+ Cancers
Ongoing TC-210 Phase 1/2 Trial in MSLN+ Cancers PHASE 1: Dose Finding PHASE 2: Expansion NSCLC NSCLC 4 n=8 n=12 Dose Level 7 (+ LD) + anti-PD1 Dose Level 6 (- LD) 3 Ovarian Cancer Dose Level 5 (+ LD) n=10 Dose Level 4 (- LD) RP2D 2 Cholangiocarcinoma Dose Level 3 (+ LD) n=10 Dose Level 2 (- LD) Indi
Slide 9: Enrollment Rules During Phase 1
Enrollment Rules During Phase 1 Modified 3+3 Dose Escalation 7 2 5x10 TC-210 T Cells/m >28 Days >28 Days >28 Days 1 Patient First Dose 1 Patient 1 Patient Second Dose 1 Patient Dose Level 1 Dose Level 0 (No LD) (With LD) 9 LD: LymphodepletionEnrollment Rules During Phase 1 Modified 3+3 Dose Escalati
Slide 10: TC-210 Study: Patient Flow
TC-210 Study: Patient Flow MSLN Pre-Screen Apheresis TC-210 Infusion LTFU TC-210 Manufacture 1 2 3 6 12 24 Safety and Efficacy Monitoring Screening Mesothelin Expression Lymphodepletion Regimen Clinical Trial Sites 2 § Central lab (Roche/Ventana)§ Fludarabine (F): 30 mg/m x4§ Sarah Cannon Research I
Slide 11: TC-210 Phase 1 Dose Escalation: Objectives
TC-210 Phase 1 Dose Escalation: Objectives Primary Exploratory § Expansion, persistence, phenotype, § Safety (Establish the RP2D) functionality of TC-210 T-cells § Serum cytokine levels § Immunogenicity Secondary § ORR (CR + PR) according to RECIST v1.1 § DCR (ORR + SD) § Duration of response § Surv
Slide 12: TC-210 Phase 1 Dose Escalation: Eligibility Criteria
TC-210 Phase 1 Dose Escalation: Eligibility Criteria Key Inclusion Criteria § ≥ 18 years of age § Adequate Performance Status and organ function § Pathologically confirmed MPM, NSCLC, ovarian cancer, or cholangiocarcinoma § Must have received at least 1 systemic standard of care therapy for metastat
Slide 13: Pre-Screening, Enrollment and Manufacturing Activity
Pre-Screening, Enrollment and Manufacturing Activity Patients Pre-Screened 79 § MSLN expression above enrollment cutoff in ~50% of screened patients Tumor Samples 62 Resulted § Products meeting protocol specifications have been successfully MSLN 2+/3+ in ≥ 50% viable tumor cells 30 (48) manufactured
Slide 14: Patient Characteristics
Patient Characteristics Characteristics N = 5 Median age, years (range) 61 (36-74) Cancer diagnosis Mesothelioma 4 (2 peritoneal, 2 pleural) Ovarian cancer 1 Median No. of prior therapies (range) 5 (3-9) ≥4 prior therapies, No. (%) 3 (60) Prior ICI therapy, No. (%) 3 (60) Prior anti-MSLN directed th
Slide 15: Summary of Grade ≥3 Treatment Emergent Adverse Events
Summary of Grade ≥3 Treatment Emergent Adverse Events Adverse Event N = 5 (%) Hematologic Neutropenia 4 (80) Lymphopenia 5 (100) Thrombocytopenia 1 (20) Adverse Events of Special Interest On Target / On Tumor CRS* 1 (20) Neurotoxicity 0 On Target / Off Tumor Pericarditis / Pericardial effusion 0 Ple
Slide 16: RECIST v1.1 Response Assessment Summary
RECIST v1.1 Response Assessment Summary Patients 1 2 3 4 5 Age/Sex 61/M 74/M 52/F 36/M 70/F Diagnosis MPM MPM MPM MPM Ovarian Ca MSLN 2+/3+ 90 60 73 95 55 (% of tumor cells) No. Prior Rx 8** 3 3 9 6 Pemetrexed/ Pemetrexed/ Liposomal Bridging Therapy None None Cisplatin Carboplatin doxorubicin LD Che
Slide 17: Tumor Regression Observed in All Patients with TC-210
Tumor Regression Observed in All Patients with TC-210 Overall Response Rate 40%, Disease Control Rate 100% 30 20 10 0 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 -10 -20 -17 -20 -30 -40 -42 -50 -60 ** -64 -70 -67 -80 -90 -100 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 17 ** New Lesion a
Slide 18: Early Efficacy Case Study: Patient 2
Early Efficacy Case Study: Patient 2 Partial Response (RECIST v1.1), Significant Tumor Regression (67%), Complete Metabolic Response 74-year-old male, epithelioid pleural mesothelioma Baseline Week 3 3 3 31mm, 8.5cm 15mm, 1.3cm § Extensive surgery Feb 2018 PD § Pembrolizumab Sep 2018 PD § Carboplati
Slide 19: Early Efficacy Case Study: Patient 2
Early Efficacy Case Study: Patient 2 74-year-old male, epithelioid pleural mesothelioma Baseline Week 3 (PET Scan) (PET Scan) Soluble Mesothelin & MPF Complete Metabolic Response 19 Target Lesion 2Early Efficacy Case Study: Patient 2 74-year-old male, epithelioid pleural mesothelioma Baseline Week 3
Slide 20: Early Efficacy Case Study: Patient 3
Early Efficacy Case Study: Patient 3 Significant Tumor Regression (64%) Baseline Week 12 Week 24 52-year-old female, epithelioid mesothelioma 3 3 3 33mm, 12.9cm 25mm, 8.3cm 12mm, 1.2cm § Diagnosed Aug 2015 § Left parietal pleurectomy § Cisplatin/pemetrexed Oct 2015 SD § Extensive cervical, mediastin
Slide 21: Patient Response and Follow-Up
Patient Response and Follow-Up Overall Response Rate 40%, Disease Control Rate 100% 001 - MPM 002 - MPM No LD LD 003 - MPM SD PR 004 - MPM PD Alive Death 005 - OvCa 0 1 2 3 4 5 6 7 8 9 Time (Months) 21 PatientsPatient Response and Follow-Up Overall Response Rate 40%, Disease Control Rate 100% 001 -
Slide 22: TC-210 T Cell Expansion in Peripheral Blood by qPCR
TC-210 T Cell Expansion in Peripheral Blood by qPCR TC-210 Kinetics Peak of TC-210 Expansion § Expansion of TC-210 T Cells in peripheral blood observed in all patients § Peak expansion occurred between days 7-22 post infusion § Highest expansion was observed among patients receiving lymphodepletion
Slide 23: Cytokine Levels in Peripheral Blood Following TC-210 Infusion
Cytokine Levels in Peripheral Blood Following TC-210 Infusion IFN IL-10 IL-12 Patient 1 Patient 2 Patient 3 Patient 4 IL-6 IL-8 TNF〈 Patient 5 Infusion § TC-210 infusion increased cytokine levels in peripheral blood in all patients § Higher levels were observed in Patient 2, who experienced grade 3
Slide 24: TC-210: Summary and Future Direction
TC-210: Summary and Future Direction § Encouraging data at first dose tested o Consistent clinical benefit at first TC-210 T cell dose o Manageable safety profile o High rate of patient eligibility and 100% manufacturing success § Next steps o Continue dose escalation until identification of RP2D o
Slide 25: 2020 Company Milestones
2020 Company Milestones 2H20 2H20 TC-210 TC-110 Phase 1 Follow-Up Update Phase 1 Interim Update Target: Mesothelin Target: CD19 Indications: Ovarian Cancer, NSCLC, MPM, Cholangiocarcinoma Indications: aALL, DLBCL, NHL Endpoints: Safety, Efficacy & Translational Data Endpoints: Safety, Efficacy & Tra
Slide 26: Early Clinical Validation of TRuC-T Cell Platform
Early Clinical Validation of TRuC-T Cell Platform Strengths Increased TRAFFICKING Faster T-Cell Homing Migration Receptors CONTROL TARGETING Reduced Preferential Cytokine Killing Release Long-Lasting Enhanced MICRO- Anti-Tumor PERSISTENCE Metabolism ENVIRONMENT Activity 26Early Clinical Validation o
Slide 27: Powering T Cells for Cancer Cures
&. TCR’ POWERING T CELLS FOR CANCER CURES
TCR2 Therapeutics — Technical Presentation (July 2020) on 6ix